OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time

Rhea-AI Summary

OpGen, Inc. (NASDAQ: OPGN) will report its third quarter 2022 financial results on November 10, 2022, after U.S. market close. A conference call will follow at 4:30 p.m. EST, where management will discuss the results and business updates. The presentation will be accessible via audio webcast and can be replayed until November 24, 2022. OpGen specializes in molecular diagnostics for infectious diseases and includes products like Unyvero and Acuitas AMR Gene Panel aimed at combating multidrug-resistant organisms.

ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 2022 financial results after the close of the U.S. financial markets on Thursday, November 10, 2022. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Standard Time to discuss the Company’s financial results and provide an update on business activities.

Conference Call Details

	U.S. Dial-in Number:	1-877-704-4453
	International Dial-in Number:	1-201-389-0920
	Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1569725&tp_key=91a31a2b1f
	Conference ID:	13732787

Replay Details

	U.S. Dial-in Number:	1-844-512-2921
	International Dial-in Number:	1-412-317-6671
	Replay PIN:	13732787

Following the conclusion of the conference call, a replay will be available through November 24, 2022. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website under Financials & Filings.

About OpGen, Inc.

OpGen, Inc. (Rockville, MD, U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction including ARESiss, ARESid, and AREScloud, as well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.

For more information, please visit www.opgen.com.

OpGen:

Oliver Schacht
President and CEO
InvestorRelations@opgen.com

OpGen Press Contact:
Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com

OpGen Investor Contact:
Alyssa Factor
Edison Group
afactor@edisongroup.com

 

FAQ

When will OpGen report its third quarter 2022 financial results?

OpGen will report its third quarter 2022 financial results on November 10, 2022.

What time is the OpGen conference call scheduled?

The OpGen conference call is scheduled for 4:30 p.m. Eastern Standard Time.

How can I access the OpGen financial results webcast?

The OpGen financial results webcast can be accessed through their website or directly via the provided link in the press release.

What products does OpGen offer related to infectious diseases?

OpGen's product portfolio includes Unyvero, Acuitas AMR Gene Panel, and various AI-powered bioinformatics solutions.